PSNL Personalis, Inc. Stock Quote

PSNL [NASD]

Index	-	P/E	-	EPS (ttm)	-1.81	Insider Own	2.10%	Shs Outstand	45.00M	Perf Week	8.24%
Market Cap	163.50M	Forward P/E	-	EPS next Y	-2.64	Insider Trans	22.59%	Shs Float	44.73M	Perf Month	-10.46%
Income	-81.00M	PEG	-	EPS next Q	-0.63	Inst Own	89.80%	Short Float	5.22%	Perf Quarter	-53.30%
Sales	79.80M	P/S	2.05	EPS this Y	-23.80%	Inst Trans	2.24%	Short Ratio	3.72	Perf Half Y	-72.96%
Book/sh	6.37	P/B	0.58	EPS next Y	-5.60%	ROA	-20.70%	Target Price	19.00	Perf Year	-86.74%
Cash/sh	6.00	P/C	0.61	EPS next 5Y	-	ROE	-25.70%	52W Range	3.13 - 28.47	Perf YTD	-74.21%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-20.80%	52W High	-87.07%	Beta	-
Dividend %	-	Quick Ratio	7.20	Sales past 5Y	-	Gross Margin	35.70%	52W Low	17.57%	ATR	0.39
Employees	325	Current Ratio	7.40	Sales Q/Q	-27.30%	Oper. Margin	-	RSI (14)	43.70	Volatility	10.78% 11.20%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-113.60%	Profit Margin	-	Rel Volume	0.85	Prev Close	3.91
Shortable	Yes	LT Debt/Eq	0.01	Earnings	May 04 AMC	Payout	-	Avg Volume	627.34K	Price	3.68
Recom	1.70	SMA20	-2.61%	SMA50	-21.18%	SMA200	-68.32%	Volume	534,816	Change	-5.88%

Jan-07-22

Upgrade

BofA Securities

Neutral → Buy

$27 → $23

Nov-05-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Nov-03-21

Downgrade

Needham

Buy → Hold

Oct-15-21

Resumed

Cowen

Outperform

Sep-20-21

Reiterated

Needham

Buy

$33 → $28

May-06-21

Upgrade

Oppenheimer

Perform → Outperform

$28

Jan-28-21

Initiated

Truist

Buy

$50

Jan-04-21

Downgrade

BofA Securities

Buy → Neutral

$40

Nov-12-20

Reiterated

Needham

Buy

$25 → $32

Nov-06-20

Downgrade

Oppenheimer

Outperform → Perform

Oct-19-20

Initiated

Citigroup

Buy

$35

Oct-08-20

Initiated

BTIG Research

Buy

$35

Aug-27-20

Initiated

H.C. Wainwright

Buy

$30

Aug-18-20

Initiated

Needham

Buy

$25

Sep-26-19

Upgrade

BofA/Merrill

Neutral → Buy

$22

Jul-15-19

Initiated

Oppenheimer

Outperform

$29

Jul-15-19

Initiated

Morgan Stanley

Overweight

$28

Jul-15-19

Initiated

Cowen

Outperform

Jul-15-19

Initiated

BofA/Merrill

Neutral

$27

Jun-09-22 06:54AM	Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of one-year loss Simply Wall St.
May-04-22 06:05PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	Personalis Reports First Quarter 2022 Financial Results Business Wire
01:44PM	What Is The Ownership Structure Like For Personalis, Inc. (NASDAQ:PSNL)? Simply Wall St.
Apr-28-22 04:01PM	Personalis to Present at Upcoming Investor Conferences Business Wire
Apr-26-22 08:45AM	Evaxion to Utilize Personalis ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma Business Wire -6.81%
Apr-21-22 09:00AM	Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales Business Wire -9.39%
Apr-20-22 04:01PM	Personalis to Announce First Quarter 2022 Financial Results Business Wire
Apr-18-22 09:15AM	Cathie Woods Portfolio: 10 Stocks Under $10 Insider Monkey
Apr-12-22 08:55AM	Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene Business Wire
08:30AM	Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal Platform Business Wire
Apr-11-22 09:00AM	Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022 Business Wire
Mar-31-22 04:01PM	Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference Business Wire
Mar-24-22 06:25PM	Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors Business Wire
Mar-23-22 09:01AM	Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022 Business Wire
Mar-01-22 07:36AM	Is Personalis (NASDAQ:PSNL) A Risky Investment? Simply Wall St.
Feb-24-22 06:00PM	Personalis (PSNL) Reports Q4 Loss, Lags Revenue Estimates Zacks +9.61%
04:01PM	Personalis Reports Fourth Quarter and Full Year 2021 Financial Results Business Wire
Feb-23-22 04:01PM	Personalis to Present at the Cowen 42nd Annual Health Care Conference Business Wire
Feb-17-22 03:02PM	Earnings Preview: Personalis (PSNL) Q4 Earnings Expected to Decline Zacks -8.54%
Feb-15-22 08:08AM	Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection Business Wire
Feb-10-22 04:01PM	Personalis to Announce Fourth Quarter and Full-Year Financial Results Business Wire
Feb-01-22 04:01PM	Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Business Wire
Jan-21-22 11:37AM	15 Worst Stock Picks of Cathie Wood Insider Monkey
Jan-06-22 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Business Wire
Dec-28-21 04:01PM	Personalis to Participate in the 24th Annual Needham Virtual Growth Conference Business Wire
Dec-20-21 10:38AM	Personalis (NASDAQ:PSNL) adds US$65m to market cap in the past 7 days, though investors from a year ago are still down 62% Simply Wall St.
Dec-18-21 09:15AM	Personalis Inc (PSNL) President and CEO John Stephen West Sold $1.3 million of Shares GuruFocus.com
Dec-16-21 08:45AM	Personalis Launches NeXT Personal, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity Business Wire -6.59%
Dec-07-21 04:35PM	Peninsula biotech snags $300M in ongoing early-cancer detection showdown American City Business Journals +9.94%
Nov-18-21 04:26PM	Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference Business Wire -6.11%
Nov-12-21 09:03AM	Personalis Named to Inc.'s 2021 Best-Led Companies List Business Wire
Nov-11-21 04:05PM	Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Business Wire
Nov-04-21 09:35AM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates Zacks +6.04%
07:00AM	Personalis Reports Third Quarter 2021 Financial Results Business Wire
Nov-02-21 07:01PM	Personalis Announces Updates to NeXT Platform Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers Business Wire
Oct-28-21 03:05PM	Analysts Estimate Personalis (PSNL) to Report a Decline in Earnings: What to Look Out for Zacks +7.11%
Oct-26-21 05:45PM	Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform Business Wire
04:25PM	Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development Business Wire
Oct-21-21 09:00AM	Personalis to Announce Third Quarter Financial Results on November 4, 2021 Business Wire
Oct-19-21 10:51AM	What Kind Of Investors Own Most Of Personalis, Inc. (NASDAQ:PSNL)? Simply Wall St.
Oct-18-21 12:26PM	Cathie Woods Top 15 Small-Cap Stock Picks Insider Monkey
Oct-13-21 09:03AM	Personalis Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement Business Wire
Oct-12-21 09:10AM	Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing Business Wire
Sep-20-21 06:21AM	Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying Motley Fool
Sep-18-21 10:50PM	Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth Business Wire
Sep-09-21 07:52AM	Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought Motley Fool
Aug-26-21 04:01PM	Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference Business Wire
Aug-25-21 04:01PM	Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development Business Wire
Aug-17-21 11:42AM	Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth Simply Wall St.
Aug-04-21 05:45PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Personalis Reports Second Quarter 2021 Financial Results Business Wire
Aug-03-21 04:01PM	Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Business Wire
Aug-02-21 04:05PM	Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients Business Wire
Jul-28-21 03:03PM	Earnings Preview: Personalis (PSNL) Q2 Earnings Expected to Decline Zacks
Jul-21-21 04:01PM	Personalis to Announce Second Quarter Financial Results on August 4, 2021 Business Wire
Jun-22-21 09:01AM	Personalis Announces NeXT Level Biomarkers Symposium Business Wire
Jun-11-21 07:00AM	Did You Miss Personalis' (NASDAQ:PSNL) 99% Share Price Gain? Simply Wall St.
Jun-02-21 04:03PM	Personalis Announces Delivery of the 125,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program Business Wire
May-18-21 04:01PM	Personalis to Participate at the Oppenheimer MedTech, Tools & Diagnostics Summit Business Wire +7.03%
May-17-21 08:01AM	Personalis, Inc. to Present at Biomarkers Week Online 2021 Business Wire
May-05-21 06:05PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	Personalis Reports First Quarter 2021 Financial Results Business Wire
03:15PM	Personalis Inc to Host Earnings Call ACCESSWIRE
Apr-29-21 04:01PM	Personalis to Present at the 2021 Bank of America Healthcare Conference Business Wire
Apr-28-21 12:34PM	Earnings Preview: Personalis (PSNL) Q1 Earnings Expected to Decline Zacks
Apr-21-21 04:01PM	Personalis to Report First Quarter 2021 Financial Results on May 5, 2021 Business Wire +7.63%
Apr-12-21 07:24AM	What Is The Ownership Structure Like For Personalis, Inc. (NASDAQ:PSNL)? Simply Wall St.
Apr-08-21 04:07PM	Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform® Business Wire
Apr-01-21 08:22AM	Personalis (PSNL) Stock Jumps 7.9%: Will It Continue to Soar? Zacks
Mar-29-21 04:03PM	Personalis Announces Collaboration with MapKure to Use Personalis NeXT Platform for Clinical Trials and Companion Diagnostic Development Business Wire -6.25%
Mar-08-21 05:00PM	Personalis Announces Changes to its Board of Directors Business Wire -8.25%
Feb-25-21 04:01PM	Personalis Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire -8.68%
02:45PM	Personalis Inc to Host Earnings Call ACCESSWIRE
Feb-22-21 08:48PM	CORRECTING and REPLACING Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021 Business Wire -10.37%
Feb-17-21 09:01AM	Natera and Personalis Partner for Personalized Monitoring in Oncology Business Wire
Feb-16-21 04:01PM	Personalis to Present at Upcoming Investor Conferences Business Wire
Feb-09-21 05:02AM	Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth Simply Wall St.
Feb-08-21 05:13PM	Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer Business Wire
Feb-04-21 04:01PM	Personalis to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference Business Wire
Jan-27-21 03:54PM	Why Personalis Stock Dropped Today Motley Fool -11.31%
Jan-26-21 10:09PM	Personalis Announces Pricing of Public Offering of Common Stock Business Wire -9.46%
04:31PM	Personalis Announces Launch of Public Offering of Common Stock Business Wire
Jan-23-21 06:40AM	If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now Motley Fool
Jan-11-21 04:01PM	Personalis Reports Preliminary Fourth Quarter 2020 Revenue Business Wire +5.39%
Dec-28-20 04:01PM	Personalis to Present at the 23rd Annual Needham Virtual Growth Conference Business Wire
Dec-17-20 09:09AM	Personalis Announces the Launch of NEOPS, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response Business Wire
09:07AM	Personalis Announces the Launch of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development Business Wire
Dec-11-20 06:49PM	Is PSNL A Good Stock To Buy Now? Insider Monkey
Dec-09-20 04:07PM	Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program Business Wire +6.85%
Nov-18-20 08:00AM	Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event Business Wire
Nov-16-20 09:00AM	Personalis® to Present at the AMP Annual Meeting 2020 Business Wire
Nov-09-20 04:12PM	Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting Business Wire
Nov-06-20 09:31AM	Benzinga's Top Upgrades, Downgrades For November 6, 2020 Benzinga
Nov-05-20 05:15PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Personalis Reports Third Quarter 2020 Financial Results Business Wire
03:45PM	Personalis Inc to Host Earnings Call ACCESSWIRE
Oct-29-20 12:35PM	Analysts Estimate Personalis (PSNL) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-27-20 04:01PM	Personalis to Participate in Upcoming Investor Conferences Business Wire
Oct-22-20 04:01PM	Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020 Business Wire

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chen Richard	Chief Medical Officer	Jun 17	Sale	3.29	1,565	5,149	146,488	Jun 21 04:52 PM
Tachibana Aaron	Chief Financial Officer	Jun 17	Sale	3.29	3,440	11,318	231,943	Jun 21 04:48 PM
Moore Stephen Michael	General Counsel	Jun 15	Sale	3.24	1,832	5,936	73,885	Jun 17 05:11 PM
Chen Richard	Chief Medical Officer	Jun 15	Sale	3.24	6,818	22,090	148,053	Jun 17 05:08 PM
Tachibana Aaron	Chief Financial Officer	Jun 15	Sale	3.24	6,818	22,090	235,383	Jun 17 05:02 PM
Tachibana Aaron	Chief Financial Officer	Jun 02	Sale	3.59	4,187	15,031	242,201	Jun 06 05:36 PM
Chen Richard	Chief Medical Officer	Jun 02	Sale	3.59	421	1,511	154,871	Jun 06 05:30 PM
West John Stephen	President and CEO	May 16	Sale	4.86	2,408	11,703	382,444	May 18 06:16 PM
Tachibana Aaron	Chief Financial Officer	May 16	Sale	4.86	1,286	6,250	246,388	May 18 06:17 PM
Moore Stephen Michael	General Counsel	May 16	Sale	4.86	664	3,227	75,717	May 18 06:15 PM
Chen Richard	Chief Medical Officer	May 16	Sale	4.86	1,286	6,250	155,830	May 18 06:14 PM
Moore Stephen Michael	General Counsel	May 02	Sale	5.53	5,733	31,703	76,381	May 04 05:38 PM
West John Stephen	President and CEO	Apr 20	Option Exercise	1.84	45,061	82,912	384,852	Apr 22 05:25 PM
West John Stephen	President and CEO	Apr 13	Option Exercise	1.84	64,430	118,551	404,221	Apr 15 06:24 PM
Lightspeed Venture Partners Se	Affiliate of 10% Owner	Mar 03	Buy	9.83	261,011	2,565,738	2,084,240	Mar 04 08:27 PM
Lightspeed Venture Partners Se	Affiliate of 10% Owner	Mar 03	Buy	10.38	4,750	49,305	4,750	Mar 04 08:27 PM
Lightspeed Venture Partners Se	Affiliate of 10% Owner	Mar 02	Buy	9.96	48,989	487,930	1,823,229	Mar 04 08:27 PM
Chen Richard	Chief Medical Officer	Mar 02	Sale	10.18	471	4,795	157,334	Mar 04 06:09 PM
Tachibana Aaron	Chief Financial Officer	Mar 02	Sale	10.18	4,511	45,922	251,441	Mar 04 06:08 PM
Chen Richard	Chief Medical Officer	Jan 28	Sale	9.93	705	7,001	157,805	Feb 01 06:05 PM
Tachibana Aaron	Chief Financial Officer	Jan 28	Sale	9.93	705	7,001	255,952	Feb 01 06:04 PM
West John Stephen	President and CEO	Jan 19	Sale	11.01	64,503	710,178	285,457	Jan 19 07:22 PM
West John Stephen	President and CEO	Jan 18	Sale	11.73	35,484	416,227	349,960	Jan 19 07:22 PM
Chen Richard	Chief Medical Officer	Dec 17	Sale	12.80	1,563	20,006	158,510	Dec 20 07:10 PM
West John Stephen	President and CEO	Dec 17	Sale	12.80	2,732	34,970	385,444	Dec 20 07:00 PM
Tachibana Aaron	Chief Financial Officer	Dec 17	Sale	12.80	3,437	43,994	256,657	Dec 20 07:59 PM
West John Stephen	President and CEO	Dec 16	Sale	13.42	97,268	1,305,337	388,176	Dec 17 09:17 PM
Chen Richard	Chief Medical Officer	Dec 02	Sale	12.92	419	5,413	80,073	Dec 06 06:06 PM
Tachibana Aaron	Chief Financial Officer	Dec 02	Sale	12.92	4,184	54,057	180,094	Dec 06 06:05 PM
West John Stephen	President and CEO	Nov 30	Sale	13.65	100,000	1,365,000	485,444	Dec 02 05:49 PM
West John Stephen	President and CEO	Nov 17	Sale	17.04	2,348	40,010	585,444	Nov 19 06:15 PM
Tachibana Aaron	Chief Financial Officer	Nov 17	Sale	17.04	1,253	21,351	184,278	Nov 19 06:14 PM
Chen Richard	Chief Medical Officer	Nov 17	Sale	17.04	1,253	21,351	79,781	Nov 19 06:12 PM
West John Stephen	President and CEO	Oct 12	Sale	19.33	100,000	1,933,000	587,792	Oct 14 06:24 PM
Tachibana Aaron	Chief Financial Officer	Sep 17	Sale	21.25	3,152	66,980	185,531	Sep 21 06:36 PM
Chen Richard	Chief Scientific Officer	Sep 17	Sale	21.25	1,088	23,120	81,034	Sep 21 06:35 PM
Tachibana Aaron	Chief Financial Officer	Sep 02	Sale	21.92	3,820	83,734	188,683	Sep 07 05:51 PM
Chen Richard	Chief Scientific Officer	Sep 02	Sale	21.92	291	6,379	82,122	Sep 07 05:50 PM
Chen Richard	Chief Scientific Officer	Aug 06	Option Exercise	0.00	15,564	0	102,413	Aug 10 05:19 PM
Chen Richard	Chief Scientific Officer	Aug 06	Sale	21.22	4,436	94,132	82,413	Aug 10 05:19 PM
West John Stephen	President and CEO	Jul 08	Sale	22.54	110,000	2,479,400	635,520	Jul 12 05:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience